Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies

ABSTRACT The heavily glycosylated HIV-1 envelope glycoprotein (Env) is the sole viral antigen present at the surface of virions and infected cells, representing the main target for antibody responses. The FDA-approved small molecule temsavir acts as an HIV-1 attachment inhibitor by preventing Env-CD...

Full description

Bibliographic Details
Main Authors: Marianne Boutin, Dani Vézina, Shilei Ding, Jérémie Prévost, Annemarie Laumaea, Lorie Marchitto, Sai Priya Anand, Halima Medjahed, Gabrielle Gendron-Lepage, Catherine Bourassa, Guillaume Goyette, Andrew Clark, Jonathan Richard, Andrés Finzi
Format: Article
Language:English
Published: American Society for Microbiology 2022-06-01
Series:mBio
Subjects:
HIV-1
Env glycoprotein
entry inhibitors
attachment inhibitors
fostemsavir
BMS-663068
Online Access:https://journals.asm.org/doi/10.1128/mbio.00577-22

Internet

https://journals.asm.org/doi/10.1128/mbio.00577-22

Similar Items